Andrew James Martin, PhD, and Anthony J. Olszanski, RPh, MD, on Oral Nicotinamide to Reduce Nonmelanoma Skin Cancers 
    		2015 ASCO Annual Meeting
    	
    	
    	
    
        Andrew James Martin, PhD, of NHMRC Clinical Trials Centre, University of Sydney, and Anthony J. Olszanski, RPh, MD, of Fox Chase Cancer Center, discuss a form of vitamin B3 that reduced the incidence of new nonmelanoma skin cancers in high-risk patients (Abstract 9000).
    
    
    
    
Related Videos
    
       
       
    		David E. Gerber, MD, and James L. Mulshine, MD
		
		
        
		
		
		
		James L. Mulshine, MD, of Rush University Medical Center, and David E. Gerber, MD, of The University of Texas Southwestern Medical Center, discuss the ALCHEMIST trial, an NCI initiative to address the role of molecular testing and targeted therapies for earlier-stage lung disease (Abstract TPS7583).
			
			
     	
    
       
       
    		Julie Gralow, MD and Clifford A. Hudis, MD
		
		
        
		
		
		
		Julie Gralow, MD, of the University of Washington/Seattle Cancer Care Alliance, and Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, discuss this important SWOG trial and why oral bisphosphonates should be made available in the United States (Abstract 503).
			
			
     	
    
       
       
    		Andrew D. Seidman, MD, and Clifford A. Hudis, MD
		
		
        
		
		
		
		Clifford A. Hudis, MD, and Andrew D. Seidman, MD, of Memorial Sloan Kettering Cancer Center, discuss the use of the decision support system Watson for Oncology and results of the iCanCare study on second opinions (Abstracts 566 and 6508).
			
			
     	
    
       
       
    		Carolyn Jean Presley, MD, and James L. Mulshine, MD
		
		
        
		
		
		
		James L. Mulshine, MD, of Rush University Medical Center, and Carolyn Jean Presley, MD, of Yale Cancer Center/Yale School of Medicine, discuss the burden on patients and the Medicare system as new lung cancer CT guidelines are put into effect and treatment of early-stage NSCLC increases (Abstract 7533).
			
			
     	
    
       
       
    		Claus Garbe, MD
		
		
        
		
		
		
		Claus Garbe, MD, of the University of Tuebingen, discusses the survival of sentinel lymph node biopsy–positive melanoma patients with and without complete lymph node dissection (Abstract LBA9002).